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ABSTRACT
Background. Protein tyrosine phosphatase type IVA
member 3 (PTP4A3/PRL-3), a metastasis-associated
phosphatase, plays multiple roles in cancer metastasis. We
investigated PTP4A3/PRL-3 expression and its correlation
with the clinicopathological features and prognosis in
hepatocellular carcinoma (HCC).
Methods. Gene expression profiles of PTP4A3/PRL-3
were obtained in poorly differentiated HCC tissues. The
results were validated independently by TaqMan gene
expression assays and immunohistochemical analysis.
Results. According to the microarray profiles, PTP4A3/
PRL-3 was upregulated in patients with poorly differenti-
ated disease compared to patients with well-differentiated
disease with hepatic backgrounds associated with hepatitis
B or C. Validation analysis showed that the PTP4A3/PRL-
3 mRNA and protein levels were significantly associated
with poor differentiation (P \ 0.0001), high serum
a-fetoprotein (P \ 0.01), high serum protein induced by
vitamin K absence/antagonist-II (PIVKA-II), and hepatic
vascular invasion (P \ 0.05). The expression of PTP4A3/
PRL-3 protein was also correlated with advanced cancer
stages (P \ 0.01); this resulted in a significantly poorer
prognosis in both overall (P = 0.0024) and recurrence-free
survival (P = 0.0227). According Cox regression univari-
ate analysis, the positive expression of PTP4A3/PRL-3 was
a poor risk prognostic factor (OS, P = 0.0031; recurrence-
free survival, P = 0.0245). Cox regression multivariate
analysis indicated that high PTP4A3/PRL-3 expression was
an independent, unfavorable prognostic factor for overall
survival (hazard ratio 0.542; P = 0.048).
Conclusions. PTP4A3/PRL-3 might be closely associated
with HCC progression, invasion, and metastasis. Its high
expression had a negative impact on the prognosis of HCC
patients. This strongly suggests that PTP4A3/PRL-3 should
be considered as a prognostic factor. Further analysis
should be pursued to evaluate it as a novel prognostic
target.
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors worldwide.1 Although surgical
resection is a potentially curative treatment for HCC, and
despite improved diagnosis and advances in surgical and
nonsurgical therapies, the clinical outcome of HCC
remains poor.2,3 It is therefore crucial to understand the
molecular mechanisms of this highly aggressive cancer,
and finding molecular markers that can predict the tumor
prognosis is important for developing new therapies.
Protein tyrosine phosphatase type IVA, member 3
(PTP4A3), is also known as phosphatase of regenerating
liver-3 (PRL-3). It is a member of the PRL subgroup of
protein tyrosine phosphatases, which are a large family of
regulatory enzymes that function actively with protein tyro-
sine kinases in signaling pathways and participate in many
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fundamental physiological processes.4–6 Accumulating evi-
dence suggests that PRL phosphatases, especially PRL-3,
have been involved in the proliferation, growth regulation,
increased cell motility, metastasis, and invasion in different
types of cancers.7–9 It has been reported that PRL-3 was
specifically overexpressed in liver metastases derived from
colorectal cancer as well as invasive breast cancer, ovarian
cancer, gastric cancer, esophageal squamous cell carcinoma,
and squamous cell carcinoma of the cervix.10–13 Further-
more, PRL-3 was demonstrated to be a useful indicator for
tumor recurrence and patient outcome in several human
cancers.14–21 In HCC, PRL-3 was found to be overexpres-
sed, and it was closely associated with tumor invasion and
angiogenesis.22 However, up to now, the expression of
PTP4A3/PRL-3 and its clinicopathological and prognostic
significance in HCC have not been determined.
DNA microarray technology has enabled us to analyze
the genome-wide profile of gene expression specific to
malignant tumors. Such studies have the potential to lead to
the development of a novel, molecular-targeted therapy for
HCC.23 In the present study, PTP4A3/PRL-3 was obtained
in poorly differentiated HCC tissues by examining the
genome-wide expression profile of HCC generated by
cDNA microarray. The results of training analyses, which
were validated independently by TaqMan gene expression
assays and immunohistochemically, and their clinicopath-
ological significance, including the prognosis and
recurrence of HCC, were investigated.
MATERIALS AND METHODS
Patients and Preparation of Tissue Samples
We enrolled 256 patients undergoing partial hepatec-
tomy for the first time of primary HCC between 2001 and
2010 at the Tokyo Medical and Dental University Hospital.
The hepatitis virus status of these patients was as follows:
59 patients were positive for hepatitis B virus (HBV) sur-
face antigen, 144 were positive for hepatitis C virus (HCV)
antibody, and 53 were negative for both. In addition, 90
patients were pathologically diagnosed as having well-
differentiated HCC, 91 moderately differentiated, and 75
poorly differentiated. In this study, we selected patients
who were virus infected and whose HCC was either well or
poorly differentiated, according to pathological diagnosis.
A total of 142 primary liver tumor specimens (virus-neg-
ative patients and moderate-differentiation HCC tissues
were excluded) and 10 normal liver specimens (which
came from metastatic liver cancer patients whose origin
tumor was diagnosed as colorectal cancer) were collected
during surgery, snap frozen in liquid nitrogen, and stored at
-80 C. A portion of the tissue sample was fixed in 10 %
formaldehyde solution and embedded in paraffin for his-
topathological analysis. Written informed consent was
obtained from these patients, and the institutional review
board approved the study. The patients were followed up
with assays of their serum level of a-fetoprotein (AFP) and
protein induced by vitamin K absence or antagonists II
every month, and by ultrasonography, computed tomog-
raphy (CT), and magnetic resonance imaging every 3
months.
Microarray Gene Expression
Gene expression analysis was performed on the 42 pri-
mary HCC patients whose samples were used as training
sets, and samples from the remaining 100 patients were
used for validation analysis. Total RNA from those tissues
was prepared with the RNeasy Mini Kit together with
RNase-free DNase (Qiagen, Hiden, Germany). The integ-
rity of the RNA obtained was assessed by an Agilent 2100
BioAnalyzer (Agilent Technologies, Palo Alto, CA, USA).
All samples had a RNA integrity number (RIN) of [5.0.
Using 2 lg of total RNA specimen tissues, cRNAs were
prepared with a one-cycle target labeling and control
reagents kit (Affymetrix, Santa Clara, CA, USA), and the
microarray hybridization was carried out on Human Gen-
ome U133 2.0 chips (Affymetrix) according to the
manufacturer’s protocol.
Analysis of Gene Expression Data
A total of 42 training microarray data sets, including 15
HCC cases associated with HBV infection and 27 HCC
cases associated with HCV infection, were normalized by
the robust multiarray average (RMA) method by R statis-
tical software, version 2.12.1, with the BioConductor
package. Estimated gene expression levels were obtained
in log2-transformed values, and 62 control probe sets were
removed for further analysis. The fold change (FC) values
were calculated by the ratio of the geometric means of the
gene expression levels between the well-differentiated and
poorly differentiated groups. A Wilcoxon rank sum test
was performed to estimate the significance levels of the
differences in gene expression between the two groups. A
hierarchical clustering with the selected genes was per-
formed with R software using the Euclidean distance and
complete linkage method.
Quantitative Real-Time Polymerase Chain Reaction
(RT-PCR)
A total of 2 lg of tissue RNA was reverse transcribed to
cDNA with a high-capacity cDNA reverse transcription kit
(Applied Biosystems) according to the manufacturer’s
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instructions. The TaqMan MGB probe for PTP4A3/PRL-3
(Hs02341135_m1) was used for gene expression assays,
and each PCR reaction was repeated at least three times.
For the quantitative analysis of specific mRNA expression,
CT values were calculated by 7500 SDS software. The data
were analyzed by the DDCT method (Applied Biosystems
User Bulletin 2, 1997), and 18S rRNA was used as an
internal control.
Preparation of Cell Lines and RT-PCR of PTP4A3/
PRL-3 mRNA
The human hepatoma cell lines SK-Hep1, Hep3-B, and
PLC/PRF/5 were kindly provided by the American Type
Culture Collection (Manassas, VA, USA). Huh1, Huh6,
Huh7, HLE, HLF, HepG2, JHH1, JHH2, JHH4, and JHH5
were obtained from the Human Science Research Resour-
ces Bank (Osaka, Japan). The conditions of cell culture
were reported previously.24 Total RNA was extracted with
the RNeasy Mini Kit and reverse transcribed to cDNA with
a high-capacity cDNA reverse transcription kit according
to the manufacturer’s instructions.
Immunohistochemical Staining
To further validate the expression of the candidate gene
by microarray, immunohistochemical studies were per-
formed. The primary antibody used was a polyclonal rabbit
anti-human PTP4A3 (ab50276, Abcam, Cambridge, UK),
diluted 1:400 in phosphate-buffered saline containing 1 %
bovine serum albumin. The tissue sections were stained
with an automated immunostainer (BenchMark XT; Ven-
tana Medical Systems, Tucson, AZ, USA) by using heat-
induced epitope retrieval and a standard diaminobenzidine
detection kit (Ventana). The intensity of the cytoplasmic
and nuclear membrane immunostaining for PTP4A3/PRL-
3 was graded as follows: 0, no immunostaining; 1,
immunostaining observed in \20 % of tumor cells; 2,
moderate immunostaining observed in 20–49 %; and 3,
strong and diffuse immunostaining observed in [50 % of
tumor cells. A score of 0 or 1 was considered negative,
whereas scores of 2 or 3 were considered positive. The
immunohistochemical staining was evaluated under a light
microscope by two independent investigators.
Statistical Analysis
Statistical comparisons of the clinicopathological char-
acteristics were performed by the v2 test or Fisher’s exact
test. Differences in mRNA levels between groups and the
association between clinicopathological factors were ana-
lyzed by the Student t test. The data were expressed as
mean ± standard deviation (SD). Fisher’s exact test was
performed to estimate the associated between gene
expression and the clinicopathological variables in each
group. Overall survival (OS) and recurrence-free survival
(RFS) curves were obtained by the Kaplan–Meier method
and were compared with the log-rank test. Univariate and
multivariate analyses were performed by Cox proportional
hazard models.
RESULTS
Strong Expression of PTP4A3/PRL-3 in of Poorly
Differentiated Tumors was Detected by Gene
Expression Profiling
Identification of those genes associated with the differ-
entiation of the HCCs was performed by using the gene
expression profiles obtained by the DNA microarray. First,
the gene expression analysis was performed for 15 HCC
cases associated with HBV (Fig. 1a) and 27 HCCs asso-
ciated with HCV (Fig. 1b) according to a well or poor
differentiation status of the tumor, respectively. In 54,613
probe sets, 32 probes (associated with HBV cases) (Sup-
plementary Table S2) and 160 probes (associated with
HCV cases) (Supplementary Table S3) that satisfied Wil-
coxon P \ 0.005 and FC [ 3.0 were identified as
differently expressed genes. As shown in Fig. 1a, b, the
tumors were clearly divided by hierarchical clustering for
well-differentiated (green) versus poorly differentiated
(orange) cases. Next, we selected five probes (four genes)
that had similar expression patterns associated with tumor
differentiation, and the hepatic background was also
associated HBV or HCV (P \ 0.005, FC [ 3.0) (Supple-
mentary Table S4). Interestingly, the PTP4A3/PRL-3 gene
was significantly upregulated in the poorly differentiated
tumors in both HBV- and HCV-associated cases, indicating
that PTP4A3/PRL-3 was the dominant molecule in the
poorly differentiated HCC tumors. We then investigated
the cumulative OS and tumor RFS curves of the 42 training
cases for PTP4A3/PRL-3 expression after curative surgery.
There were significant differences between the PTP4A3/
PRL-3 high and low expression groups in terms of the OS
(P = 0.0021) and RFS (P = 0.0106) rate, respectively
(Fig. 1c, d).
Clinicopathological and Molecular Factors Associated
with HCC Survival and Recurrence
We examined the association between the clinicopath-
ological factors and survivals of the 42 training patients
with primary HCCs. The clinicopathological features of the
42 training patients according their differentiation status
were studied by statistical analyses (Supplementary
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Table S1). The univariate Cox regression analysis dem-
onstrated that the prothrombin time, AFP, portal vein
invasion, advanced cancer stages, poor differentiation, and
higher PTP4A3/PRL-3 expression correlated with both
cumulative OS and RFS. The aspartate amino transferase
(AST) and hepatic vein invasion correlated only with RFS.
The other clinicopathological factors were not statistically
significant (Table 1).
Validation Study by TaqMan Gene Expression Assays
According to the training microarray analysis, the
PTP4A3/PRL-3 gene was closely correlated with poor
differentiation, poorer OS, and recurrence of HCC. To
confirm the microarray findings, the results were inde-
pendently validated by TaqMan gene expression assays.
We also tested the microarray results in training sets.
There was a significant correlation between the cDNA
microarray and TaqMan gene expression assays results in
terms of PTP4A3/PRL-3 expression (Fig. 2a). The
expression of PTP4A3/PRL-3 in poorly differentiated
HCC tissues was significantly higher than in well-dif-
ferentiated tissues of HCC patients associated with HBV
(P \ 0.01) or HCV (P \ 0.001) (Fig. 2c). This result
was validated independently in HCC tumor tissues from
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FIG. 1 Microarray analysis of human hepatocellular carcinoma.
a Hierarchical clustering of the gene expression for well-differenti-
ated (green) and poorly differentiated (orange) HBV-associated HCC
samples. b Hierarchical clustering of HCV-associated HCC samples.
These genes were identified by the Wilcoxon signed rank test
(P \ 0.005), and a more than three-fold change between the two
groups of well versus poorly differentiated HCCs. Red and blue
represent relative overexpression and underexpression, respectively.
c, d OS and RFS of 42 postoperative HCC patients associated with the
expression of the PTP4A3/PRL-3 gene in cancerous liver tissue. The
mean expression level for each gene was used as a cutoff value. Solid
or dotted lines indicate the Kaplan–Meier curves for patients with
relative overexpression and underexpression, respectively. The log-
rank test was used to assess the statistical difference between the two
groups (OS, P = 0.0021; RFS, P = 0.0106). HBV hepatitis B virus,
HCC hepatocellular carcinoma, HCV hepatitis C virus, OS overall
survival, RFS recurrence-free survival
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mRNA expression levels of PTP4A3/PRL-3 were statis-
tically significantly different between HCC and normal
liver specimens (5.29 ± 1.43 vs. 3.86 ± 0.76,
P = 0.0035, Fig. 3b, left), PTP4A3/PRL-3 was more
highly expressed in poorly differentiated disease than in
well-differentiated disease (6.21 ± 2.25 vs. 4.17 ± 1.70,
P \ 0.0001, Fig. 3b, right). The clinicopathological sig-
nificance of PTP4A3/PRL-3 mRNA expression was also
analyzed. Depending on the expression level
(means ± SD) of PTP4A3/PRL-3 mRNA, the clinico-
pathological factors were divided into two groups.
PTP4A3/PRL-3 mRNA was significantly correlated with
virus infection (P = 0.0422), serum AFP (P = 0.0047),
PIVKA-II (P = 0.0259), portal vein invasion (P =
0.0156), and vascular invasion (P = 0.0192) (Table 2).
There were no statistically significant differences
between age, gender, size of tumor, number of tumors,
tumor infiltration into the capsule, and stages of the
tumor.
Expression of PTP4A3/PRL-3 in HCC Cell Lines
The expression level of PTP4A3/PRL-3 mRNA was
evaluated in 13 hepatoma cell lines. The PTP4A3/PRL-3
mRNA was highly expressed in HCC cell lines, and there
were different expression patterns (Fig. 3c). In 2 of 13
cells, the PTP4A3/PRL-3 mRNA levels were lower than in
the known cell lines such as HLE and HLF derived from
epithelial and fibroblastic colonies in cultures of the same
undifferentiated hepatomas and did not produce AFP and
albumin. The other cells were derived from differentiated
hepatomas and produced AFP.
Immunohistochemical Detection of PTP4A3/PRL-3
in HCC Tissues and Association
with Clinicopathological Variables
Next, an immunohistochemical analysis was per-
formed for the evaluation of the clinical significance of
TABLE 1 Cox regression analysis of the overall and recurrence-free survival in the 42 training cases
Overall survival Recurrence-free survival
Univariate HR (95 % CI) P Univariate HR (95 % CI) P
Clinicopathological factors
Age (years, mean ± SD) 0.978 (0.942–1.015) 0.2392 0.990 (0.951–1.031) 0.6367
Gender (female vs. male) 0.830 (0.331–2.212) 0.7089 0.907 (0.387–2.124) 0.822
Virus infection (HBV vs. HCV) 1.331 (0.606–2.923) 0.4768 0.940 (0.438–2.016) 0.8738
AST (IU/l, mean ± SD) 1.005 (0.994–1.016) 0.3639 1.011 (1.000–1.022) 0.0423
ALT (IU/l, mean ± SD) 1.003 (0990–1.016) 0.6777 1.006 (0.993–1.019) 0.3804
Plt (9109/l, mean ± SD) 1.026 (0.956–1.100) 0.4811 1.025 (0.959–1.094) 0.468
ICG-R15 (%, mean ± SD) 1.006 (0.976–1.037) 0.6863 1.016 (0.986–1.046) 0.3063
PT (%, mean ± SD) 0.945 (0.913–0.978) 0.0013 0.967 (0.937–0.998) 0.0396
T. bil (mg/dl, mean ± SD) 1.942 (1.165–3.237) 0.0109 1.144 (0.649–2.018) 0.6411
Alb (g/dl, mean ± SD) 0.624 (0.289–1.348) 0.2302 0.690 (0.326–1.458) 0.3311
AFP (ng/ml, log10) 1.769 (1.312–2.385) 0.0002 1.767 (1.338–2.332) \0.0001
PIVKA-II (mAU/ml, log10) 1.196 (0.827–1.730) 0.3411 1.282 (0.891–1.846) 0.1813
Tumor max size (cm, mean ± SD) 1.092 (0.957–1.246) 0.1900 1.105 (0.982–1.243) 0.0965
Multiple versus solitary 0.936 (0.376–2.332) 0.8870 1.305 (0.577–2.954) 0.5227
Capsular formation (-) versus (?) 1.632 (0.761–3.501) 0.2083 0.902 (0.413–1.974) 0.7968
Capsular invasion (-) versus (?) 1.752 (0.814–3.772) 0.1517 1.295 (0.615–2.726) 0.4967
Portal vein invasion (pvp) 0.307 (0.138–0.683) 0.0038 0.185 (0.084–0.405) \0.0001
Hepatic vein invasion (pvv) 0.663 (0.244–1.806) 0.4212 0.374 (0.156–0.897) 0.0276
Vascular invasion (pvp/pvv) 0.331 (0.114–0.777) 0.0112 0.179 (0.080–0.400) \0.0001
Stage (III ? IV) versus (I ? II) 0.331 (0.114–0.777) 0.0112 0.344 (0.160–0.740) 0.0063
Degree of differentiation (poor vs. well) 4.146 (1.526–11.263) 0.0053 3.678 (1.596–8.477) 0.0022
Molecule factor
PTP4A3/PRL-3 expression (high) 3.563 (1.5.09–8.411) 0.0037 2.598 (1.217–5.545) 0.0136
HR hazard ratio, CI confidence interval, HBV hepatitis B virus, HCV hepatitis C virus, AST aspartate amino transferase, ALT alanine amino-
transferase, PLT platelet, ICG-R15 indocyanine green retention rate at 15 min, PT prothrombin time, T. bil total bilirubin, Alb albumin, AFP
a-fetoprotein, PIVKA-II protein induced by vitamin K absence or antagonists II
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PTP4A3/PRL-3 expression by using tissue samples from
100 patients with HCC. We also tested the immunore-
activity of PTP4A3/PRL-3 in the same microarray test
samples. The results for PTP4A3/PRL-3 immunostain-
ing are shown in Fig. 2d. PTP4A3/PRL-3 protein was
mainly localized in the cytoplasm and nuclear mem-
brane of the cancer cells, and rarely nuclear staining
was also seen. Consequently, the specific overexpres-
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FIG. 2 Training study:
expression of PTP4A3/PRL-3 in
HCC. a Correlation of the test
samples for PTP4A3/PRL-3
mRNA expression by cDNA
microarray and TaqMan gene
expression assays (left HBV-
associated patients, right HCV-
associated patients). b RT-PCR
products were detected by
agarose gel electrophoreses
stratified by HBV- or HCV-
associated HCC. (w Well-
differentiated, p poorly
differentiated). c The mRNA
expression levels of PTP4A3/
PRL-3 were compared between
poorly differentiated and well-
differentiated disease according
to the presence of HBV (left)
associated (P \ 0.01) or HCV
(right) associated (P \ 0.001)
HCC, respectively.
d Immunohistochemical
analysis of PTP4A3/PRL-3 in
HCC tissues from the test
samples. Top HE staining.
Middle, bottom PTP4A3/PRL-
3-high (right) or low (left)
expression (original
magnification, 9100, 9200)
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The clinicopathological significance of PTP4A3/PRL-3
expression was then evaluated in the PTP4A3/PRL-
3-positive group (n = 57) and compared to the negative
group (n = 43) of HCC patients (Table 2). The protein
expression of PTP4A3/PRL-3 was significantly correlated
with tumor differentiation (P \ 0.0001), serum AFP
(P = 0.0118), high serum PIVKA-II (P = 0.0214),
hepatic vein invasion (P = 0.0374), tumor vascular
invasion (P = 0.0198), and advanced cancer stages
(P = 0.0047).
Overexpression of PTP4A3 Protein in HCC Tissues
Associated with a Poor Prognosis
To examine the prognostic significance of PTP4A3/
PRL-3 expression, we performed a validation study on 100
patients with HCC. According to the immunostaining
analysis of HCC tissues, the OS and RFS survival were
then compared between the two groups. The PTP4A3/PRL-
3-positive group demonstrated a significantly poorer sur-
vival than the PTP4A3/PRL-3-negative group for both OS
d
PTP4A3 low expression (× 200) PTP4A3 high expression (× 200)
FIG. 2 continued
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(P = 0.0024) and RFS (P = 0.0227). We also investigated
the association between the OS and RFS rates and clini-
copathological factors, and we performed univariate and
multivariate Cox regression analyses (Table 3). The OS
was statistically significantly correlated with seven factors
such as AST, serum AFP, tumor size, tumor differentiation,
portal vein invasion, stage of tumor, and PTP4A3/PRL-3
expression. On the multivariate analysis, PTP4A3/PRL-3
expression (hazard ratio [HR] 0.542; P = 0.048), portal
vein invasion (HR 0.470; P = 0.023), and AST (HR 1.006;
P = 0.048) were statistically significant prognostic factors
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FIG. 3 Validation study: expression of PTP4A3/PRL-3 in human
HCC. a RT-PCR products were detected by agarose gel electroph-
oreses stratified by normal liver and HCC (w well, p poor) tissues.
b The mRNA expression levels of PTP4A3/PRL-3 were compared
between the HCC and normal liver tissues (NL) (P \ 0.01), and
between well-differentiated and poorly differentiated HCC tissues
(P \ 0.0001) by TaqMan gene expression assay. c The expression of
PTP4A3/PRL-3 in hepatoma cell lines. d Immunohistochemical
analysis of PTP4A3/PRL-3 in HCC tissues from the validation
samples. A representative positive immunostaining case (top) and a
negative immunostaining case (bottom) are shown. e Kaplan–Meier
estimates for the OS and RFS times with respect to PTP4A3/PRL-3
protein expression in primary HCCs. The survival rate of patients
with positive or negative PTP4A3/PRL-3 expression are indicated by
solid or dotted lines, respectively. The log-rank test results revealed a
significant difference in OS rates between the two groups
(P = 0.0024), and also a significant difference was observed for the
RFS rates between the two groups (P = 0.0227). HCC hepatocellular
carcinoma, OS overall survival, RFS recurrence-free survival
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DISCUSSION
In the present study, the gene expression profiles of
PTP4A3/PRL-3 were obtained in poorly differentiated and
well-differentiated HCC, regardless of the background of
the virus. On the basis of the training analysis, strong
PTP4A3/PRL-3 expression was significantly correlated
with the cumulative survival and recurrence-free rates of
the patients (Fig. 1c, d; Table 1). This result was validated
independently by TaqMan gene expression assays and
immunostaining. We also studied the significance of
PTP4A3/PRL-3 mRNA and protein expression, from a
clinical viewpoint, for the progression of HCC. The over-
expression of PTP4A3/PRL-3 was significantly correlated
with the serum levels of AFP and PIVKA-II, tumor vas-
cular invasion, and advanced cancer stages in HCC
patients. Similar results have been reported by Zhao
et al.,22 suggesting that PRL-3 expression was correlated
with angiogenesis and invasion through an upregulation of
matrix metalloproteinases (MMPs) or a downregulation of
E-cadherin by using limited HCC cases. PRL-3 expression
has also been reported in colon, breast, ovarian, and gastric
cancers, where its presence seems to have an important
role in the acquisition of metastatic potential.11,15–21 In
our studies, the clinical significance of PTP4A3/PRL-3
expression was noted and correlated significantly with poor
tumor differentiation (P \ 0.0001) and the OS and RFS of
HCC patients (Fig. 3e). PTP4A3/PRL-3 expression also
showed a significant correlation with a poor clinical out-
come (Table 3).
PTP4A3/PRL-3 plays multiple roles in cancer metasta-
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FIG. 3 continued
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pathways, PRL-3 induces cell differentiation, proliferation,
invasion, and metastasis.7–9 Invasion through the basement
membrane and interstitial extracellular matrix is another
key event for metastatic progression, which requires the
action of a series of proteolytic enzymes, the MMPs. The






HBV hepatitis B virus, HCV
hepatitis C virus, AFP
a-fetoprotein, PIVKA-II protein
induced by vitamin K absence
or antagonists II
Variable PTP4A3 mRNA PTP4A3 protein
n Mean ± SD P n Negative Positive P
Age (years)
\60 20 5.10 ± 2.23 0.9009 28 11 17 0.6609
C60 63 5.17 ± 2.23 72 32 40
Gender
Male 60 5.32 ± 2.38 0.2895 72 25 47 0.0126
Female 23 4.74 ± 1.70 28 18 10
Virus infection
HBV 25 4.40 ± 2.46 0.0422 33 18 15 0.1333
HCV 58 5.48 ± 2.05 67 25 42
No. of tumors
Solitary 53 5.13 ± 2.10 0.8942 71 33 38 0.3736
Multiple 30 5.20 ± 2.47 29 10 19
Tumor size (cm)
\5.0 58 4.86 ± 1.92 0.0706 70 33 37 0.2710
C5.0 25 5.83 ± 2.73 30 10 20
AFP (ng/ml)
\20 34 4.22 ± 1.85 0.0011 40 26 14 0.0004
C20 49 5.80 ± 2.24 60 17 43
\100 55 4.67 ± 2.07 0.0047 65 34 31 0.0118
C100 28 6.11 ± 2.23 35 9 26
PIVKA-II (mAU/ml)
\100 39 4.58 ± 2.38 0.0259 46 23 23 0.2268
C100 44 5.66 ± 1.96 54 20 34
\1000 59 4.82 ± 2.16 0.0313 74 37 37 0.0214
C1000 24 5.97 ± 2.20 26 6 20
Differentiation
Well 43 4.17 ± 1.70 \0.0001 46 30 16 \0.0001
Poor 40 6.21 ± 2.25 54 13 41
Infiltration to capsule (fc-inf)
Absent 35 5.30 ± 2.49 0.6177 48 20 28 0.8416
Present 48 5.05 ± 2.02 52 23 29
Portal vein invasion (pvp)
Absent 60 4.79 ± 2.21 0.0156 72 35 37 0.0770
Present 23 6.10 ± 2.00 28 8 20
Hepatic vein invasion (pvv)
Absent 71 5.00 ± 2.28 0.1310 87 41 46 0.0374
Present 12 6.05 ± 1.65 13 2 11
Vascular invasion (pvp/pvv)
Absent 53 4.73 ± 2.28 0.0192 66 34 32 0.0198
Present 30 5.91 ± 1.93 34 9 25
Tumor stages
I ? II 33 4.75 ± 1.83 0.1795 44 26 18 0.0047
III ? IV 50 5.42 ± 2.43 56 17 39
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TABLE 3 Cox regression analysis of overall and recurrence-free survival in 100 validation cases
Overall survival Recurrence-free survival
Univariate analysis Variable selection Univariate analysis Variable selection




0.996 (0.968–1.025) 0.7901 0.993 (0.966–1.021) 0.6375
Gender (female/
male)




1.142 (0.673–1.938) 0.6231 1.187 (0.730–1.931) 0.4892
AST (IU/l,
mean ± SD)
1.007 (1.001–1.014) 0.0192 1.006 (1.000–1.013) 0.048 1.005 (0.998–1.012) 0.1327
ALT (IU/l,
mean ± SD)
1.005 (0.999–1.011) 0.1096 1.004 (0.997–1.010) 0.2977
Plt (9109/l,
mean ± SD)
1.017 (0.987–1.047) 0.2822 0.999 (0.970–1.030) 0.9601
ICG-R15 (%,
mean ± SD)
0.997 (0.979–1.015) 0.7119 0.998 (0.982–1.015) 0.8202
PT (%,
mean ± SD)
0.991 (0.978–1.005) 0.2113 0.996 (0.984–1.008) 0.4896
T. bil (mg/dl,
mean ± SD)
1.212 (0.859–1.709) 0.2741 0.964 (0.676–1.369) 0.838
Alb (g/dl,
mean ± SD)
1.062 (0.756–1.491) 0.7287 0.973 (0.732–1.293) 0.8495
AFP, ng/ml
(C20 vs. \20)












0.836 (0.483–1.515) 0.5930 1.312 (0.796–2.165) 0.2869
Differentiation
(poor vs. well)




1.344 (0.822–2.197) 0.2388 1.192 (0.750–1.893) 0.4583
Portal vein
invasion
0.304 (0.177–0.523) \0.0001 0.470 (0.245–0.901) 0.023 0.251 (0.150–0.420) \0.0001 0.316 (0.165–0.603) 0.0005
Hepatic vein
invasion
0.823 (0.403–1.682) 0.5933 0.472 (0.253–0.879) 0.0181 0.654 (0.326–1.312) 0.2321
Stage (III ? IV)
versus (I ? II)





0.440 (0.255–0.759) 0.0031 0.542 (0.294–0.997) 0.048 0.578 (0.359–0.932) 0.0245 1.000 (0.556–1.798) 0.9994
HR hazard ratio, CI confidence interval, HBV hepatitis B virus, HCV hepatitis C virus, AST aspartate amino transferase, ALT alanine amino-
transferase, PLT platelet, PT prothrombin time, ICG-R15 indocyanine green retention rate at 15 min, T. bil total bilirubin, Alb albumin, AFP
a-fetoprotein, PIVKA-II protein induced by vitamin K absence or antagonists II
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they can degrade denatured collagens and type IV collagen
present in the basement membrane.25 In our training
microarray studies (Supplementary Table S2), MMP12 was
also highly expressed in poorly differentiated patients with
HCC. In addition, other members of the metalloproteinase
family such as MMP1, MMP9, and MMP10 (Wilcoxon
P \ 0.05; FC [ 1.5) were also upregulated in poorly dif-
ferentiated patients (data not shown in Supplementary
Table S2). We found significantly positive correlations between
PTP4A3/PRL-3 and MMP12 (r = 0.721, P\0.0001), MMP1
(r = 0.514, P = 0.0004), MMP9 (r = 0.501, P = 0.0006),
and MMP10 (r = 0.347, P = 0.0236) (Supplementary Fig. S1).
Several studies have suggested that a downregulation of
E-cadherin-mediated intercellular adhesion increased tumor
differentiation, invasion, and metastasis and led to a poor
prognosis in human cancers, including HCC.26,27 At present, our
microarray studies also showed that the downregulation of
E-cadherin in tumor tissues was associated with hepatic vascular
invasion, moderate to poor differentiation, and the recurrence of
patients with HCC (data not shown). However, there was no
statistical correlation between PTP4A3/PRL-3 expression and
E-cadherin expression on the basis of the training sets analysis
(Supplementary Fig. S1). This result suggested a role for
PTP4A3/PRL-3 overexpression in HCC, and its ectopic
expression in different cell types is correlated with the induction
of metastatic phenotypes, such as invasion and motility capa-
bilities. PTP4A3/PRL-3 expression was predominantly
correlated with poorly differentiated tumor cells and increased
invasion potential through an upregulation of MMPs.
In the present study, we showed that PTP4A3/PRL-3
was predominantly localized in the cytoplasm and nuclear
membrane by immunostaining. The expression of mem-
brane-associated PRL-3 may induce a dephosphorylation
of target substrates at the cell membrane, thus modulating
the organization of the plasma membrane in such a way to
promote cell motility and invasion.8 The membrane
structures associated with PRL-3 including ruffles, protru-
sions, and some vacuolar-like membrane extensions could
represent another opportunity for intervention. These
membrane structures have been demonstrated to play a role
in cell movement and invasion.28
Several recent studies have demonstrated the capability
of PRL-3 to regulate multiple signaling cascades, including
the PI3K-Akt, Rho, and Csk/Src pathways, which are cru-
cial for both cell cycle progression and cell migration.29,30
PRL-3-enhanced cell migration is dependent on the pres-
ervation of its catalytic function, and the consensus
phosphatase motif will potentially be a therapeutic target.
Prenylation-dependent association could effectively block
the function of PRL-3 in cell migration and invasion.8
Aberrant PTP4A3/PRL-3 expression may be closely related
to poor tumor differentiation, tumor invasion, and poorer
survival in HCC patients, and this accelerated
hepatocarcinogenesis may be positively regulated by he-
patoepithelial cell migration, thus promoting tumor
progression and the establishment of the new vasculature
needed for tumor survival and expansion. However, at this
time, we are not able to analyze any data to support this
hypothesis. Further study is required to verify these
possibilities.
In conclusion, PTP4A3/PRL-3 was identified as one of
the overexpressed molecules in HCC tissues. PTP4A3/
PRL-3 might be closely associated with HCC progression,
invasion, and metastasis, and its strong expression had a
negative impact on the prognosis of HCC patients. This
suggests that PRL-3 should be considered as a prognostic
factor. Further attention should be paid to abnormalities in
phosphatase of PRL-3 in HCC progression as a potential
target for therapy.
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